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Index (BMI) was signiﬁcantly associated with positive expendi-
tures. Higher BMI was correlated with more positive expendi-
tures. The most appropriate framework for the GLM was the
Gamma distribution. The GLM showed that higher BMI was
associated with greater expenditures. Age, gender, and marital
status (separated and never married) were signiﬁcantly as-
sociated with health care expenditures. Degree of education
(Bachelor and Masters) was also signiﬁcantly related but 
negatively correlated. CONCLUSIONS: Health care expendi-
tures are signiﬁcantly associated with BMI using a gamma dis-
tribution, where age, gender, marital status and education are
also signiﬁcant.
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IN SPAIN
Echevarria A1, Betegón L2, Badia X2
1Sanoﬁ Aventis, Madrid, Spain, 2H.O.R.-Europe, Barcelona, Spain
OBJECTIVES: Obesity has become an important public health
issue because of its link to high rates of avoidable and prema-
ture morbidity and mortality, especially due to its association
with severe cardiovascular diseases and cancer. The objective of
this study is to describe the mortality attributed to obesity in
Spain in 2000 and its associated costs. METHODS: Mortality
associated with obesity was obtained by combining mortality
data for the general population and the PAR (Population Attrib-
utable Risk). Loss of potential productive life years attributable
to obesity was estimated, based on activity rates of population
under 65 years old. The costs associated to premature death were
then obtained by multiplying by mean wage ﬁgures. RESULTS:
18.7% of all the deaths could be attributed to obesity. This mor-
tality was similar in males and females (10.116 vs 11.537). The
life years potentially lost attributable to obesity were 23,510, dis-
tributed as follows: 1015 for DM type 2, 422 for hypertension,
8925 for ischemic heart disease, 3854 for stroke, 61 for
osteoarthritis, 3330 for colorectal cancer, 897 for ovarian cancer,
3649 for breast cancer, 1359 for vesicle cancer. The loss of pro-
ductivity years, based on activity rates for population under 65
years was 12.309, meaning a loss of €294 million. CONCLU-
SIONS: This economic approach to premature death shows how
deep is the impact of obesity on the productivity of our country.
But obesity and its comorbidities increase with age, reaching its
highest prevalence after 65 years old, meaning that the real
impact of obesity in mortality in general is even more signiﬁcant.
Given that abdominal obesity has been proved to be a speciﬁc
risk factor for cardiovascular events, and that its prevalence 
is higher than obesity itself, this analysis could be completed 
by including this parameter, once the data are available in the
literature.
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OBJECTIVES: Rimonabant is a new agent currently seeking
approval by the FDA for the indications of smoking cessation
and treatment of obesity. This study estimates the cost–utility
ratio of rimonabant for the treatment of obesity using data from
two phase–III clinical trials. METHODS: Data from the Rimon-
abant in Obesity (RIO) Europe and RIO Lipids trials, two ran-
domized, double-blinded, placebo-controlled, parallel group,
ﬁxed-dose, multicenter studies, were used to model utilities
gained as increase in quality of life due to a temporary weight
loss during a one-year treatment with rimonabant. In this study,
two separate analyses were conducted: ﬁrst, treatment with
rimonabant 20mg/d plus dietary modiﬁcation versus placebo
plus dietary modiﬁcation and second, comparison of treatment
as above with a hypothetical no intervention group. The second
analysis assumed no reduction in BMI [kg/m2] and zero costs for
the no intervention group. The temporary weight loss for the
treatment and placebo group was calculated assuming a weight
regain to baseline within 3 years after treatment cessation. Costs
included drug acquisition costs (estimated based on costs for
comparable agents), physician ofﬁce visits and dietary counsel-
ing. Efﬁcacy estimates were discounted at 3%. RESULTS:
Reduction in BMI was 2.395 and 0.601 for treatment and
placebo, respectively. In the second analysis, comparison to no
intervention, treatment resulted in a BMI reduction of 3.133.
The incremental cost–utility ratio is $38,884 per QALY com-
paring treatment to placebo and $28,364 per QALY compared
to no intervention. Sensitivity analysis revealed that the results
are sensitive to variations in acquisition costs and sustainability
of weight loss. CONCLUSIONS: Rimonabant is able to increase
quality of life by reducing body weight. This beneﬁt is achieved
at considerable costs; however, the cost–utility ratios are well
below the currently accepted thresholds.
OBESITY—Methods and Concepts
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OBJECTIVE: To predict effects over time on cardiometabolic
risk factors of adding rimonabant to diet and exercise in over-
weight/obese patients. Both weight-dependent and weight-
independent effects of treatment were examined in order to carry
out a Discrete Event Simulation (DES). The DES predicts the
time-dependent course of individual patients’ data according to
treatment. METHODS: Data were taken from 4 RIO trials in
over 6600 overweight/obese patients who received once-daily
rimonabant 20mg (or placebo) on top of diet and exercise. Time-
dependent functions of individual changes in weight, waist cir-
cumference, cholesterol, HDL-cholesterol, triglycerides, HbA1c,
fasting glucose, and blood pressure were required for the DES.
Change over time was analyzed in pooled trial data using a two-
step process: 1) Logistic regressions predicted whether the para-
meter would decrease, and 2) fractional polynomials predicted
change as a function of time and other factors. Random-effects
were included to account for within and between patient vari-
ance. RESULTS: One year of treatment induced cardiometabolic
improvements following a curvilinear course with steep initial
changes and subsequent stabilization after six to nine months.
To properly reﬂect these time-dependent changes, several time
parameters were required in each equation. The degree of change
over time depended on baseline levels and other patient charac-
teristics and on weight changes, but rimonabant 20mg provided
an additional, weight-independent, statistically-signiﬁcant, effect
(OR for worsening 0.36–0.88 depending on outcome consid-
ered). CONCLUSIONS: Multivariate time-dependent analytic
techniques can provide the detailed estimates required for dis-
crete event simulation. Growth curves enable estimation of the
course of each simulated individual over time by providing for
realistic modeling of risks and facilitate probabilistic sensitivity
analyses. These analyses provided a detailed, accurate reﬂection
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of rimonabant’s effects, showing that its beneﬁcial impact is
present even when accounting for any reductions in weight, sug-
gesting that there is an effect beyond weight loss.
OBESITY—Patient Reported Outcomes
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THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED
QUALITY OF LIFE AMONG US ADULTS
Olesen AC, Liu GG, Chen SY
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: To test the impact of body mass index (BMI) on
health-related quality of life (HRQOL) in overweight and obese
individuals. METHODS: Data were obtained from the 2002
Medical Expenditure Panel Survey (MEPS). MEPS collects data
on health care use, insurance, access, and satisfaction, along with
basic demographic and health status information for a repre-
sentative sample of the US civilian non-institutionalized popula-
tion. Our weighted sample consists of 207,969,360 adults.
Regression analyses were used to detect independent effects of
HRQOL (using EQ-5D US valuation and EQ VAS) on over-
weight and obese individuals. RESULTS: After adjusting for
com-morbidities, smoking status, and socio-demographic vari-
ables, respondents with a self-reported BMI >25.0kg/m2
reported impaired quality of life. Health-related quality of life
diminished with each increasing level of BMI (p < 0.01). Addi-
tionally, HRQOL signiﬁcantly diminished with increasing age 
(p < 0.01). CONCLUSIONS: Our ﬁndings suggest a signiﬁcant
impact of BMI on changes in HRQOL that is independent of 
co-morbidities and socio-demographic variables.
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OBJECTIVES: To evaluate the self-image of women suffering
from overweight, using a validated questionnaire. METHODS:
Pharmacists who took part in this project gave 3 questionnaires
to all their customers who had purchased a cartane oil (80%
conjugated linoleic acids) treatment, explaining that the ﬁrst
questionnaire had to be ﬁlled in immediately after having bought
the product and theothers, after 6 and 10 weeks of treatment.
Once completed, the questionnaire had to be mailed in its pre-
paid envelop by the subject. Questionnaire were then collected,
typed in then analyzed anonymously. Self-image was evaluated
by BISS scale. The hereby analysis was obtained from the ﬁrst
118 ﬁlled in and returned questionnaires (inclusion, 6 & 10
weeks). The population was entirely made up of women with an
mean age of 43.5 years, mean weight of 67.6kg and average
height of 162cm. The BMI calculated using the two latter vari-
ables was of 25.5. RESULTS: For the SF-12 scale, mean scores
upon inclusion were respectively of 47.2 and 40.6 for the phys-
ical and mental dimension. Six weeks later, these same scores
were respectively of 45.6 and 45.6. Improvement is signiﬁcant
for the mental dimension. For the <<Self-image>> scale (BISS),
scores were 22.8 upon inclusion and 28.46 weeks later. The dif-
ference was signiﬁcant, hence putting forward an improvement
in the body’s image. After 10 weeks of treatment with cartane
oil the effect is sustained, self-image is signiﬁcantly improved
(33.1). CONCLUSIONS: This result is conﬁrmed through the
signiﬁcant improvement of the physical & mental dimension of
the SF-12. mean scores were respectively of 52.9 and 44.4 for
the physical and mental dimension.
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OBJECTIVES: To assess the impact of overweight/obesity on
health-related quality of life (HRQL) and health utility in the
U.S. METHODS: Adults (age >= 18) in the 2000 and 2002
Medical Expenditure Panel Survey (MEPS) were classiﬁed as
underweight (BMI < 18.5), normal weight (BMI: 18.5–24.9),
overweight (BMI: 25–29.9), obese (BMI: 30–39.9), and extreme
obese (BMI: >= 40). HRQL was measured using the SF-12
mental score and physical score. Underweight adults were
excluded form the analyses. Health utility was measured using
EQ-5D index score and visual analogue scale (EQ-VAS). A strat-
iﬁed matching method was used to compare overweight, obese,
and extreme obese samples with the corresponding normal
weight samples matched by age, gender, race, current smoking
status, and physical activity level. Effect sizes (ES) were esti-
mated. Bonferroni method was used to adjust for multiple com-
parisons. MEPS individual weights were applied to achieve
nationally representative statistics. RESULTS: Of the 36,897
adults in the study sample, 13,521 were with normal weight,
13,631 overweight, 8435 obese, and 1310 extremely obese.
Descriptive results showed that normal weight sample had the
highest average scores in all the HRQL and health utility mea-
sures. These ﬁndings were further supported by the results using
the stratiﬁed matching method. Compared to matching normal
weight adults, overweight adults had similar SF-12 mental scores
and EQ-VAS scores, but signiﬁcantly lower SF-12 physical scores
(ES = 6.24, p < 0.01) and EQ-5D index (ES = 3.72, p < 0.01).
On average, both obese and extremely obese adults had lower
SF-12 mental score (ES = 5.25 and 17.23, respectively), SF-12
physical score (ES = 23.78 and 60.04, respectively), EQ-5D index
(ES = 16.92 and 49.99, respectively), and EQ-VAS score (ES =
19.17 and 45.33, respectively). All differences were signiﬁcant at
1%. CONCLUSIONS: Our study showed that obesity is a con-
dition associated with signiﬁcant reduction of physical and
mental HRQL and health utility among adults in the United
States. Overweight had a negative impact on physical HRQL and
health utility.
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OBJECTIVES: To compare health-related quality of life
(HRQOL) using the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite) questionnaire in subjects with or without abdom-
inal obesity (AO deﬁnition: waist circumference >102/88cm for
men/women, respectively). METHODS: Prospective Obesity
Cohort of Economic Evaluation and Determinants (PROCEED)
is an ongoing international, Internet-based, longitudinal, obser-
vational cohort of overweight/obese subjects [body mass index
(BMI) > or = 25kg/m2], aged 35–75, intending to lose weight.
The IWQOL-Lite is a validated 31-item self-reported question-
naire, speciﬁcally designed for HRQOL assessment in obesity,
and comprises 5 domains (Physical Function, Self-esteem, Sexual
Life, Public Distress, Work) and a total score. Using two-sample
t-tests, baseline IWQOL scores for USA subjects were compared
between AO groups overall; between genders within the sub-
